NIH Swiss Mice Research Articles

Different ketogenesis strategies lead to disparate seizure outcomes

BackgroundDespite the introduction of new medicines to treat epilepsy over the last 50 years, the number of patients with poorly-controlled seizures remains unchanged. Metabolism-based therapies are an underutilized treatment option for this population. We hypothesized that two different means of systemic ketosis, the ketogenic diet and intermittent fasting, would differ in their acute seizure test profiles and mitochondrial respiration. MethodsMale NIH Swiss mice (aged 3–4 weeks) were fed for 12–13 days using one of four diet regimens: ketogenic diet (KD), control diet matched to KD for protein content and micronutrients (CD), or CD with intermittent fasting (24 h feed/24 h fast) (CD-IF), tested post-feed or post-fast. Mice were subject to the 6 Hz threshold test or, in separate cohorts, after injection of kainic acid in doses based on their weight (Cohort I) or a uniform dose regardless of weight (Cohort II). Mitochondrial respiration was tested in brain tissue isolated from similarly-fed seizure-naïve mice. ResultsKD mice were protected against 6 Hz-induced seizures but had more severe seizure scores in the kainic acid test (Cohorts I & II), the opposite of CD-IF mice. No differences were noted in mitochondrial respiration between diet regimens. InterpretationKD and CD-IF do not share identical antiseizure mechanisms. These differences were not explained by differences in mitochondrial respiration. Nevertheless, both KD and CD-IF regimens protected against different types of seizures, suggesting that mechanisms underlying CD-IF seizure protection should be explored further.

Strain differences in the susceptibility to the gut-brain axis and neurobehavioural alterations induced by maternal immune activation in mice.

There is a growing realization that the severity of the core symptoms of autism spectrum disorders and schizophrenia is associated with gastrointestinal dysfunction. Nonetheless, the mechanisms underlying such comorbidities remain unknown. Several genetic and environmental factors have been linked to a higher susceptibility to neurodevelopmental abnormalities. The maternal immune activation (MIA) rodent model is a valuable tool for elucidating the basis of this interaction. We induced MIA with polyinosinic-polycytidylic acid (poly I:C) at gestational day 12.5 and assessed behavioural, physiological and molecular aspects relevant to the gut-brain axis in the offspring of an outbred (NIH Swiss) and an inbred (C57BL6/J) mouse strain. Our results showed that the specific MIA protocol employed induces social deficits in both strains. However, alterations in anxiety and depression-like behaviours were more pronounced in NIH Swiss mice. These strain-specific behavioural effects in the NIH Swiss mice were associated with marked changes in important components of gut-brain axis communication: the endocrine response to stress and gut permeability. In addition, MIA-induced changes in vasopressin receptor 1a mRNA expression in the hypothalamus were observed in NIH Swiss mice only. Taken together, these data suggest that genetic background is a critical factor in susceptibility to the gut-brain axis effects induced by MIA.

Neuroinflammatory Responses in a Mouse Model of Tetramethylenedisulfotetramine‐Induced Status Epilepticus

Tetramethylenedisulfotetramine (TETS) is a GABAA receptor antagonist that is considered a chemical threat agent due to its ease of synthesis and its potent bioactivity in humans. Acute exposure to TETS can trigger seizures that evolve into status epilepticus (SE), and death. The current medical countermeasure for treating acute intoxication with seizurogenic chemicals like TETS includes the administration of benzodiazepines such as diazepam or midazolam. When administered 40 min post‐exposure in a mouse model of TETS‐induced SE, these positive allosteric modulators of the GABAA receptor are effective in stopping seizures and reducing mortality from ~90% to ~25%. The goal of this project was to determine the efficacy of this intervention in mitigating the neuroinflammatory response following TETS‐induced SE, with the objective of determining a feasible window of time for therapeutic intervention. In the current study, adult male NIH Swiss mice were pretreated with riluzole (10 mg/kg, i.p.) 10 min prior to receiving a lethal dose of TETS (0.2 mg/kg, i.p.). Control animals received vehicle in place of TETS and benzodiazepine. Animals were continuously monitored by EEG and/or scored for seizure behavior to confirm that TETS exposure elicited electrographic and/or behavioral seizures. At 10 or 40 min after the first myoclonic body twitch, animals were administered either diazepam (1.8 mg/kg, i.p.) or midazolam (1.8 mg/kg, i.m.) to terminate the persistent seizures. At 72h post‐intoxication, animals were perfused with fixative and brains were removed for FluoroJade C (FJC) labeling to assess neurodegeneration, and for GFAP and IBA1 immunohistochemistry to quantify neuroinflammation. Relative to vehicle control, GFAP immunoreactivity was significantly increased in the piriform cortex of all TETS‐exposed groups regardless of time of benzodiazepine administration. Midazolam was not superior to diazepam in protecting against neurodegeneration or neuroinflammation. These findings do not support the hypothesis that earlier treatment with either benzodiazepine is more effective in mitigating TETS‐induced neuropathology.Support or Funding InformationSupported by the NINDS CounterACT Program (grant # U54 NS079202).This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

Evaluation of hyperbaric oxygen (HBO2) as a treatment for hyperalgesia associated with naloxone‐precipitated withdrawal in morphine‐dependent mice

Opioid dependence has become a major problem in the United States. Withdrawal from opioid drugs is associated with hyperalgesia (increased sensitivity to a pain stimulus) which may contribute to relapse [Carcoba et al., J Addict Dis 30(3): 258–70, 2012]. Hyperbaric oxygen (HBO2) is 100% oxygen at higher than atmospheric pressure. HBO2 has recently been shown to be effective at decreasing physical signs of withdrawal in morphine‐dependent mice, and there is a growing body of research showing that HBO2 is effective at decreasing pain in clinical conditions and in preclinical modeling [Nicoara et al., Brain Res. 1648:434–7, 2016; Efrati et al., PLOS One 10(5)1–25, 2015; Gibbons at al., Brain Res. 1537:111–6, 2013]. The effectiveness of HBO2 to decrease hyperalgesia caused by opioid withdrawal in an animal model of drug dependence was evaluated in this study. Male and female NIH Swiss mice were made dependent upon morphine by injecting animals s.c. with twice‐daily escalating doses of morphine for 4 consecutive days. On the 5th day, animals were given a final injection of the highest dose of morphine and injected i.p. with 1.0 mg/kg naloxone 8 hours after the final morphine injection. Animals were treated with 30 min of HBO2 at 3.5 atmospheres absolute or room air 60 min prior to naloxone injection. Nociception was evaluated using the tail withdrawal, hot plate and paw pressure tests every 10 min for 30 min after naloxone injection. Baseline levels of nociception for each endpoint were taken prior to induction of morphine dependence. Male and female animals exhibited hyperalgesia in the hot plate and paw pressure tests but not the tail withdrawal test. HBO2 significantly decreased the amount of hyperalgesia in the hot plate and paw pressure tests in male animals. In female animals, HBO2 had no effect on hyperalgesia in the hot plate test but significantly decreased the level of hyperalgesia associated with the paw pressure test. While no hyperalgesia was seen in the tail withdrawal test, HBO2 did produce significant antinociception in male and female animals. These intriguing results show that HBO2 is capable of reducing hyperalgesia associated with opioid withdrawal and warrant further investigation. Furthermore, these results help support previous findings showing that HBO2 may be effective at decreasing symptoms of opioid withdrawal.Support or Funding InformationThis research was supported by the Marchionne 12‐month Fellowship from the Department of Psychology at Washington State University, NIH Grant AT‐007222, and the Honors College Distinguished Professorship from Washington State University.This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

Aberrant expression of miR-451a contributes to 1,2-dichloroethane-induced hepatic glycerol gluconeogenesis disorder by inhibiting glycerol kinase expression in NIH Swiss mice.

The identification of aberrant microRNA (miRNA) expression during chemical-induced hepatic dysfunction will lead to a better understanding of the substantial role of miRNAs in liver diseases. 1,2-Dichloroethane (1,2-DCE), a chlorinated organic toxicant, can lead to hepatic abnormalities in occupationally exposed populations. To explore whether aberrant miRNA expression is involved in liver abnormalities mediated by 1,2-DCE exposure, we examined alterations in miRNA expression patterns in the livers of NIH Swiss mice after dynamic inhalation exposure to 350 or 700 mg m-3 1,2-DCE for 28 days. Using a microarray chip, we discovered that only mmumiR-451a was significantly upregulated in the liver tissue of mice exposed to 700 mg m-3 1,2-DCE; this finding was validated by quantitative real-time polymerase chain reaction. In vitro study revealed that it was metabolite 2-chloroacetic acid, not 1,2-DCE that resulted in the upregulation of mmu-miR-451a in the mouse AML12 cell line. Furthermore, our data showed that the upregulation of mmu-miR-451a induced by 2-chloroacetic acid could suppress the expression of glycerol kinase and lead to the inhibition of glycerol gluconeogenesis in mouse liver tissue and AML12 cells. These observations provide evidence that hepatic mmu-miR-451a responds to 1,2-DCE exposure and might induce glucose metabolism disorders by suppressing the glycerol gluconeogenesis process.

1,2-Dichloroethane Induces Reproductive Toxicity Mediated by the CREM/CREB Signaling Pathway in Male NIH Swiss Mice.

1,2-Dichloroethane (1,2-DCE) is a widely used chlorinated organic toxicant but little is known about the reproductive disorders induced by its excessive exposure. To reveal 1,2-DCE-induced male reproductive toxicity and to elucidate the underlying mechanisms, we exposed male National Institutes of Health Swiss mice to 1,2-DCE by inhalation at 0, 100, 350, and 700 mg/m3 for 6 h/day, for 1 and 4 weeks. Our findings showed a significant decrease in body weight with increased testis/body weight ratio, reduced sperm concentration and induced malformation of spermatozoa, and vacuolar degeneration of germ cells in the seminiferous tubules of testes in mice exposed to 1,2-DCE. Cyclic adenosine monophosphate (cAMP)-response element binding protein (CREB) and cAMP-response element modulator (CREM) were significantly inhibited by 1,2-DCE. This is consistent with the declines in the transducer of regulated CREB activity 1 and activator of CREM in testis, which results in the decrease in lactate dehydrogenase C and testis-specific kinase 1 in the testes. Moreover, the activation of p53 and Bax with the inhibition of Bcl-2 might be the reason for the upregulation of caspase-3 in the apoptosis, as detected by TdT-mediated dUTP nick-end labeling assay in the testes induced by 1,2-DCE. Finally, elevated testosterone levels were found along with increased levels of gonadotropin-releasing hormone, cAMP, luteinizing hormone (LH), and LH receptors in the testes. These findings suggest that 1,2-DCE inhibits CREM/CREB signaling cascade and subsequently induces apoptosis associated with p53 activation and mitochondrial dysfunction. This also results in induced malformation of spermatozoa, reduced sperm concentration, and pathological impairment of the testes.

Anti-diabetic actions of esculentin-2CHa(1-30) and its stable analogues in a diet-induced model of obesity-diabetes.

Actions of esculentin-2CHa(1-30) (GFSSIFRGVAKFASKGLGKDLAKLGVDLVA) and its analogues, ([D-Arg7, D-Lys15, D-Lys23]-esculentin-2CHa(1-30) and [Lys15-octanoate]-esculentin-2CHa(1-30), were evaluated in high-fat fed NIH Swiss mice with impaired glucose tolerance and insulin resistance. Twice-daily i.p. administration of the esculentin-2CHa(1-30) peptides (75nmol/kg body weight) or exendin-4 (25nmol/kg) for 28days reduced body weight, without altering cumulative energy intake. All peptides reduced blood glucose levels by 6-12mmol/l concomitant with lower plasma insulin levels, with significance evident from day 6. All peptides improved glucose tolerance, insulin sensitivity, blood glucose profile over 24h and decreased HbA1c to a similar extent as exendin-4. The peptides also reduced high fat diet-induced increases in plasma GLP-1 and glucagon. None of the peptides altered bone mineral density/content or lean mass but decreased fat mass. Islets isolated from peptide-treated mice exhibited improved glucose-, alanine- and GLP-1-stimulated insulin secretion. Islet morphometric analyses revealed that exendin-4 and the esculentin-2CHa(1-30) peptides significantly reduced islet, beta and alpha cell areas compared to high-fat controls. Esculentin-2CHa(1-30) peptides markedly reduced high fat diet-induced increase in beta cell proliferation and apoptosis. Peptide treatments had beneficial effects on expression of islet genes (Ins1, Slc2a2, Pdx1) and skeletal muscle genes involved in insulin action (Slc2a4, Pdk1, Irs1, Akt1). High-fat diet significantly increased LDL cholesterol which was reduced by the acylated esculentin-2CHa(1-30) analogue. Peptide treatments did not alter circulating concentrations of amylase and marker enzymes of liver function, indicating a lack of toxicity. These data indicate that esculentin-2CHa(1-30) and its analogues may be useful for improvement of blood glucose control and weight loss in type 2 diabetes.

Influence of indigenous microbiota on experimental toxoplasmosis in conventional and germ-free mice.

Toxoplasmosis represents one of the most common zoonoses worldwide. Its agent, Toxoplasma gondii, causes a severe innate pro-inflammatory response. The indigenous intestinal microbiota promotes host animal homoeostasis and may protect the host against pathogens. Germ-free (GF) animals provide an important tool for the study of interactions between host and microbiota. In this study, we assessed the role of indigenous microorganisms in disease development utilizing a murine toxoplasmosis model, which includes conventional (CV) and GF NIH Swiss mice. CV and GF mice orally inoculated with T.gondii had similar survival curves. However, disease developed differently in the two animal groups. In CV mice, intestinal permeability increased and levels of intestinal pro-inflammatory cytokines were altered. In GF animals, there were discrete epithelial degenerative changes and mucosal oedema, but the liver and lungs displayed significant lesions. We conclude that, despite similar survival curves, CV animals succumb to an exaggerated inflammatory response, whereas GF mice fail to produce an adequate systemic response.

Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice.

Conventional antidepressants lack efficacy for many patients (treatmentresistant depression or TRD) and generally take weeks to produce full therapeutic response in others. Emerging data has identified certain drugs such as ketamine as rapidly-acting antidepressants for major depressive disorder and TRD. Scopolamine, a drug used to treat motion sickness and nausea, has also been demonstrated to function as a rapidly-acting antidepressant. The mechanisms associated with efficacy in TRD patients and rapid onset of action have been suggested to involve a-Amino-3-hydroxy- 5-methyl-4-isoxazolepropionic acid (AMPA) receptor and mammalian target of rapamycin (mTOR) signaling. Since the work on these mechanisms with scopolamine has been limited, the present set of experiments was designed to further explore these mechanisms of action. Male, NIH Swiss mice demonstrated a robust and immediate antidepressant signature with ketamine or scopolamine when studied under the forced-swim test. The AMPA receptor antagonist NBQX prevented this antidepressant-like effect of scopolamine and ketamine. An orally-bioavilable mTOR inhibitor (AZD8055) also attenuated the antidepressant- like effects of scopolamine and ketamine. Scopolamine was also shown to augment the antidepressant- like effect of the selective serotonin reuptake inhibitor citalopram. When given in combination, scopolamine and ketamine acted synergistically to produce antidepressant-like effects. Although drug interaction data suggested that additional mechanisms might be at play, metabolomic analysis of frontal cortex and plasma from muscarinic M1+/+ and M1 -/- mice given scopolamine or vehicle did not reveal any hints as to the nature of these additional mechanisms of action. Overall, the data substantiate and extend the idea that AMPA and mTOR signaling pathways are necessary for the antidepressant-like effects of scopolamine and ketamine, mechanisms that appear to be of general significance for TRD therapeutic agents.

Physiological frailty index (PFI): quantitative in-life estimate of individual biological age in mice.

The development of healthspan-extending pharmaceuticals requires quantitative estimation of age-related progressive physiological decline. In humans, individual health status can be quantitatively assessed by means of a frailty index (FI), a parameter which reflects the scale of accumulation of age-related deficits. However, adaptation of this methodology to animal models is a challenging task since it includes multiple subjective parameters. Here we report a development of a quantitative non-invasive procedure to estimate biological age of an individual animal by creating physiological frailty index (PFI). We demonstrated the dynamics of PFI increase during chronological aging of male and female NIH Swiss mice. We also demonstrated acceleration of growth of PFI in animals placed on a high fat diet, reflecting aging acceleration by obesity and provide a tool for its quantitative assessment. Additionally, we showed that PFI could reveal anti-aging effect of mTOR inhibitor rapatar (bioavailable formulation of rapamycin) prior to registration of its effects on longevity. PFI revealed substantial sex-related differences in normal chronological aging and in the efficacy of detrimental (high fat diet) or beneficial (rapatar) aging modulatory factors. Together, these data introduce PFI as a reliable, non-invasive, quantitative tool suitable for testing potential anti-aging pharmaceuticals in pre-clinical studies.

Esculentin-2CHa(1-30) and its analogues: stability and mechanisms of insulinotropic action.

The insulin-releasing effects, cellular mechanisms of action and anti-hyperglycaemic activity of 10 analogues of esculentin-2CHa lacking the cyclic C-terminal domain (CKISKQC) were evaluated. Analogues of the truncated peptide, esculentin-2CHa(1-30), were designed for plasma enzyme resistance and increased biological activity. Effects of those analogues on insulin release, cell membrane integrity, membrane potential, intracellular Ca2+ and cAMP levels were determined using clonal BRIN-BD11 cells. Their acute effects on glucose tolerance were investigated using NIH Swiss mice. d-Amino acid substitutions at positions 7(Arg), 15(Lys) and 23(Lys) and fatty acid (l-octanoate) attachment to Lys at position 15 of esculentin-2CHa(1-30) conveyed resistance to plasma enzyme degradation whilst preserving insulin-releasing activity. Analogues, [d-Arg7,d-Lys15,d-Lys23]-esculentin-2CHa(1-30) and Lys15-octanoate-esculentin-2CHa(1-30), exhibiting most promising profiles and with confirmed effects on both human insulin-secreting cells and primary mouse islets were selected for further analysis. Using chemical inhibition of adenylate cyclase, protein kinase C or phospholipase C pathways, involvement of PLC/PKC-mediated insulin secretion was confirmed similar to that of CCK-8. Diazoxide, verapamil and Ca2+ omission inhibited insulin secretion induced by the esculentin-2CHa(1-30) analogues suggesting an action on KATP and Ca2+ channels also. Consistent with this, the analogues depolarised the plasma membrane and increased intracellular Ca2+ Evaluation with fluorescent-labelled esculentin-2CHa(1-30) indicated membrane action, with internalisation; however, patch-clamp experiments suggested that depolarisation was not due to the direct inhibition of KATP channels. Acute administration of either analogue to NIH Swiss mice improved glucose tolerance and enhanced insulin release similar to that observed with GLP-1. These data suggest that multi-acting analogues of esculentin-2CHa(1-30) may prove useful for glycaemic control in obesity-diabetes.

Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice.

Aims/hypothesisAbnormal cannabidiol (Abn-CBD) and AS-1269574 are potent selective agonists for GPR55 and GPR119, respectively. The present study evaluated the actions and ability of these small-molecule agonists to counteract experimental diabetes in mice.MethodsDiabetes was induced in NIH Swiss mice by five consecutive daily intraperitoneal injections of 40 mg/(kg body weight) streptozotocin. Diabetic mice received daily oral administration of Abn-CBD or AS-1269574 (0.1 μmol/kg) or saline vehicle (0.9% wt/vol. NaCl) over 28 days. Body weight, food intake, fluid intake, plasma glucose, insulin, glucose tolerance, insulin release, lipid profile and pancreatic morphology were examined. Mechanism of action of agonists was assessed in acute studies using incretin-receptor-knockout mice.ResultsAbn-CBD and AS-1269574 decreased plasma glucose (20–26%, p < 0.05) and increased circulating insulin (47–48%, p < 0.05) by 10–28 days, compared with saline-treated diabetic controls. Food intake and polydipsia were reduced by both agonists (21–23%, p < 0.05 and 33–35%, p < 0.01, respectively). After 28 days of treatment, plasma glucagon concentrations were reduced (p < 0.01) and glucose tolerance was enhanced by 19–44% by Abn-CBD (p < 0.05 or p < 0.001) and AS-1269574 (p < 0.05 to p < 0.001). Plasma insulin responses were improved (p < 0.01) and insulin resistance was decreased (p < 0.05 or p < 0.01) in both Abn-CBD- and AS-1269574-treated groups. Triacylglycerols were decreased by 19% with Abn-CBD (p < 0.05) and 32% with AS-1269574 (p < 0.01) while total cholesterol was reduced by 17% (p < 0.01) and 15% (p < 0.05), respectively. Both agonists enhanced beta cell proliferation (p < 0.001) although islet area was unchanged. Acute studies in Gipr- and Glp1r-knockout mice revealed an important role for the glucagon-like peptide 1 (GLP-1) receptor in the actions of both agonists, with the glucose-lowering effects of Abn-CBD also partly mediated through the glucose-dependent insulinotropic peptide (GIP) receptor.Conclusions/interpretationThese data highlight the potential for fatty acid G-protein-coupled receptor-based therapies as novel insulinotropic and glucose-lowering agents acting partly through the activation of incretin receptors.Electronic supplementary materialThe online version of this article (doi:10.1007/s00125-016-4108-z) contains peer-reviewed but unedited supplementary material, which is available to authorised users.

Hyperbaric oxygen treatment suppresses withdrawal signs in morphine-dependent mice

Hyperbaric oxygen (HBO2) therapy reportedly reduces opiate withdrawal in human subjects. The purpose of this research was to determine whether HBO2 treatment could suppress physical signs of withdrawal in opiate-dependent mice. Male NIH Swiss mice were injected s.c. with morphine sulfate twice a day for 4 days, the daily dose gradually increasing from 50mg/kg on day 1 to 125mg/kg on day 4. On day 5, withdrawal was precipitated by i.p. injection of 5.0mg/kg naloxone. Mice were observed for physical withdrawal signs, including jumping, forepaw tremor, wet-dog shakes, rearing and defecation for 30min. Sixty min prior to the naloxone injection, different groups of mice received either a 30-min or 60-min HBO2 treatment at 3.5atm absolute. HBO2 treatment significantly reduced naloxone-precipitated jumping, forepaw tremor, wet-dog shakes, rearing and defecation. Based on these experimental findings, we concluded that treatment with HBO2 can suppress physical signs of withdrawal syndrome in morphine-dependent mice.

Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice

The antidiabetic potential of thirteen novel dogfish glucagon derived analogues were assessed in vitro and in acute in vivo studies. Stable peptide analogues enhanced insulin secretion from BRIN-BD11 β-cells (p < 0.001) and reduced acute glycaemic responses following intraperitoneal glucose (25 nmol/kg) in healthy NIH Swiss mice (p < 0.05–p<0.001). The in vitro insulinotropic actions of [S2a]dogfish glucagon, [S2a]dogfish glucagon-exendin-4(31-39) and [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL, were blocked (p < 0.05–p<0.001) by the specific GLP-1 and glucagon receptor antagonists, exendin-4(9-39) and (desHis1Pro4Glu9)glucagon amide but not by (Pro3)GIP, indicating lack of GIP receptor involvement. These analogues dose-dependently stimulated cAMP production in GLP-1 and glucagon (p < 0.05–p<0.001) but not GIP-receptor transfected cells. They improved acute glycaemic and insulinotropic responses in high-fat fed diabetic mice and in wild-type C57BL/6J and GIPR-KO mice (p < 0.05–p<0.001), but not GLP-1R-KO mice, confirming action on GLP-1 but not GIP receptors. Overall, dogfish glucagon analogues have potential for diabetes therapy, exerting beneficial metabolic effects via GLP-1 and glucagon receptors.

English

Mansoa alliacea contains high concentrations of chemicals thought to be associated with the suppression of tumor growth. Additionally, this plant has been reported to possess analgesic, anti-fungal, and anti-bacterial properties, thereby providing other potential benefits for cancer patients. Low doses of a water extract of M. alliacea were applied to a cancerous and non-cancerous cell line. Doses between 1.254 to 10.04 mg/ml of extract applied to T3-HA cancer cells inhibited cell growth, but higher doses of 29.92 to 89.6 mg/ml destroyed colonies of the cancer cells. Application of the extract to NIH Swiss mouse cell cultures resulted in the inhibition of growth at higher concentrations, but at a concentration of 10.14 mg/ml, cell growth began to increase after three days. However, cell death was less at lower concentrations than that of T3-HA cancer cells, thereby confirming that lower concentrations of Ajo de Monte will inhibit cancer cell growth as well as initially inhibit non-cancer cells. Thus, M. alliacea extract selectively targets T3-HA mouse cancer cells but not NIH Swiss embryonic mouse cells. Future research may consider the use of this plant for human cancer patients. &nbsp; Key words: Mansoa alliacea, Garlic Vine, Ajo de Monte, cancer

I10W]tigerinin-1R enhances both insulin sensitivity and pancreatic beta cell function and decreases adiposity and plasma triglycerides in high-fat mice.

We have previously described the insulinotropic activities of [I10W]tigerinin-1R (RVCSAIPLPWCH.NH2) in vitro. In this study, we investigated the effects of the peptide on nutrient homoeostasis in mice with diet-induced obesity and insulin resistance. Male NIH Swiss mice were maintained on a high-fat diet for 12 weeks prior to the study. Twice-daily intraperitoneal injections of [I10W]tigerinin-1R (75nmol/kg body weight) were administered for 28days. Body weight, energy intake, body fat content, and plasma concentrations of triglyceride, cholesterol, non-fasting glucose and insulin were monitored. Effects of the peptide on glycaemic control were measured by glucose tolerance and insulin sensitivity tests. Pancreatic hormone content and insulin secretory responses of islets isolated from treated and untreated mice were examined. Immunohistochemical analysis was performed to study possible changes in islet morphology. Administration of [I10W]tigerinin-1R to high-fat-fed mice produced significant (P<0.05) decreases in plasma glucose, glucagon and triglyceride concentrations and an increase in plasma insulin compared to high-fat-fed controls. No changes in body weight or energy intake were observed with peptide treatment, but glycaemic control was significantly improved in response to oral or intraperitoneal glucose. Insulin sensitivity and secretory responses of islets to established insulin secretagogues were also significantly improved in peptide-treated mice. Total body fat, pancreatic insulin and glucagon contents, islet, beta and alpha cell areas were all significantly decreased in treated mice. This study shows that [I10W]tigerinin-1R improves insulin sensitivity, islet function and glycaemic control in high-fat-fed mice and has potential as a template for development of novel anti-diabetic agents.

GPR39 receptors and actions of trace metals on pancreatic beta cell function and glucose homoeostasis.

G-protein-coupled receptor 39 (GPR39) has been implicated in glucose homoeostasis, appetite control and gastrointestinal tract function. This study used clonal BRIN-BD11 cells and mouse pancreatic islets to assess the insulin-releasing actions of trace metals believed to act via GPR39, and the second messenger pathways involved in mediating their effects. Micromolar concentrations of Zn(2+), Cu(2+), Ni(2+) and Co(2+) were examined under normoglycaemic and hyperglycaemic conditions. Mechanistic studies investigated changes of intracellular Ca(2+), cAMP generation and assessment of cytotoxicity by LDH release. Cellular localisation of GPR39 was determined by double immunohistochemical staining. All trace metals (7.8-500µmol/l) stimulated insulin release with Cu(2+) being the most potent in isolated islets, with an EC50 value of 87μmol/l. Zn(2+) was the most selective with an EC50 value of 125μmol/l. Enhancement of insulin secretion was also observed with Ni(2+) (179μmol/l) and Co(2+) (190μmol/l). These insulin-releasing effects were confirmed using clonal BRIN-BD11 cells which exhibited enhanced intracellular Ca(2+) (p<0.05-p<0.001) and cAMP generation (p<0.05-p<0.001) in response to trace metals. Oral administration of Zn(2+), Ni(2+) and Cu(2+) (50µmol/kg together with 18mmol/kg glucose) decreased the glycaemic excursion (p<0.05-p<0.01) and augmented insulin secretion (p<0.05-p<0.01) in NIH Swiss mice. This study has demonstrated the presence of GPR39 and the insulinotropic actions of trace metals on BRIN-BD11 cells and pancreatic beta cells, together with their antihyperglycaemic actions in vivo. These data suggest that development of agonists capable of specifically activating GPR39 may be a useful new therapeutic approach for diabetes management.

The frog skin host-defense peptide CPF-SE1 improves glucose tolerance, insulin sensitivity and islet function and decreases plasma lipids in high-fat fed mice

The frog skin host-defense peptide CPF-SE1 has previously been shown to stimulate the in vitro release of insulin from clonal BRIN-BD11 β-cells. In this study, the in vivo effects of the peptide were investigated in male NIH Swiss mice maintained on a high-fat diet to induce obesity and insulin resistance. Insulin-secretory responses of islets isolated from treated and untreated mice and changes in islet morphology were also examined. Total body fat, plasma glucagon, triglyceride and cholesterol concentrations were measured at the end of the treatment period. Acute intraperitoneal administration of CPF-SE1 (75nmol body weight) to high-fat fed mice together with glucose (18mmol/kg body weight) improved glucose tolerance and insulin responses compared to high-fat fed controls. Long term administration of CPF-SE1 (twice-daily administration of 75nmol/kg body weight for 28 days) did not affect body weight or energy intake but decreased circulating glucose and increased insulin concentrations. Insulin sensitivity and insulin-secretory responses of islets to secretagogues were also significantly improved at 28 days in peptide-treated mice. In addition, significant decreases in plasma glucagon concentrations, pancreatic insulin and glucagon content, islet and beta cell area, body fat and plasma triglyceride levels were observed in CPF-SE1 treated with mice. In conclusion, CPF-SE1 improves beta cell function, insulin sensitivity and glycaemic control whilst reducing total body fat and circulating triglyceride levels. The peptide shows potential for development into an agent for treatment of patients with metabolic syndrome and type 2 diabetes.

Mo2029 Differential Activity of NHE3 and NHE2 in the Small Intestine of Irradiated Mice

Tight junctions are formed by mature enterocytes and create an efficient barrier that has the necessary machinery for electrolyte and nutrient absorption. Radiotherapy causes epithelial barrier dysfunction leading to increased macromolecular translocation into the systemic compartment causing endotoxemia and inflammatory response. Recently, it was shown that glucose and some amino acids (AAs) activated active anion secretion and/ or increased paracellular permeability, whereas our mitigating amino acids mixture (MAAM) comprised of lysine, glycine, tryptophan, tyrosine, aspartic acid, isoleucine, threonine, valine, and serine increased electrolyte absorption and decreased paracellular permeability. The mechanism by which these amino acids tightened the mucosal barrier was not known. Therefore, studies were undertaken to determine the mechanism by which MAAM tightened the mucosal barrier. NIH Swiss mice were irradiated using a 137Cs source. Radiation dose-dependent and time-dependent (0, 6, 12, 24, 48, 72, and 144 hr after irradiation) changes in transepithelial electrical resistance (TEER) and dilution potential (DP) and the relative permeability of Cland Na+ (PCl/PNa) were measured. Transmission electron microscopy (TEM) images, Western blot analysis, and immunohistochemistry (IHC) for the cell junction protein complex (Claudin 1, 2, 5, Nectin, and E-cadherin) were performed at similar time points. Radiation resulted in a dose-dependent increase in conductance (43.3 ± 1.2, 29.5 ± 1.2, 48.2 ± 2.3, 48.9 ± 1.7, 38.7 ± 1.2 mS at 0, 1, 3, 5, 7 Gy, respectively). Similarly, time-dependent changes in conductance showed a maximal increase occurring in the first 6 hr (46.3 ± 1.5); there was no significant difference with increasing time after irradiation. Treatment with MAAM resulted in a significant decrease in conductance. DP studies showed that MAAM restored ion selectivity. TEM showed disruption of the cell junction complex and formation of clear space between the cells as early as 6 hr after irradiation. The changes persisted for the duration of the experiment (6 days). MAAM prevented cell junction disruption in mice; this was identifiable at 6 hr after irradiation. Western analysis and IHC showed a radiation dose-dependent increase in Claudin 1, 2, 5, Nectin, and E-cadherin except at 7 Gy. MAAM further increased Claudin 1, 2, 5, Nectin, and E-cadherin across all radiation doses. MAAM treatment decreased paracellular permeability. TEM showed disruption of the cell junction complex that peaked at 6 hours and was corrected using MAAM. Western analysis and IHC showed that radiation-induced alterations in the cell junction protein complex were further corrected in the MAAM group. We conclude that the disruption in the barrier results from changes in the cell junction complex and that MAAM restores the barrier function by correcting these changes.

Mo2028 A Functional Approach to Improve Barrier Function in Irradiated Mice

Tight junctions are formed by mature enterocytes and create an efficient barrier that has the necessary machinery for electrolyte and nutrient absorption. Radiotherapy causes epithelial barrier dysfunction leading to increased macromolecular translocation into the systemic compartment causing endotoxemia and inflammatory response. Recently, it was shown that glucose and some amino acids (AAs) activated active anion secretion and/ or increased paracellular permeability, whereas our mitigating amino acids mixture (MAAM) comprised of lysine, glycine, tryptophan, tyrosine, aspartic acid, isoleucine, threonine, valine, and serine increased electrolyte absorption and decreased paracellular permeability. The mechanism by which these amino acids tightened the mucosal barrier was not known. Therefore, studies were undertaken to determine the mechanism by which MAAM tightened the mucosal barrier. NIH Swiss mice were irradiated using a 137Cs source. Radiation dose-dependent and time-dependent (0, 6, 12, 24, 48, 72, and 144 hr after irradiation) changes in transepithelial electrical resistance (TEER) and dilution potential (DP) and the relative permeability of Cland Na+ (PCl/PNa) were measured. Transmission electron microscopy (TEM) images, Western blot analysis, and immunohistochemistry (IHC) for the cell junction protein complex (Claudin 1, 2, 5, Nectin, and E-cadherin) were performed at similar time points. Radiation resulted in a dose-dependent increase in conductance (43.3 ± 1.2, 29.5 ± 1.2, 48.2 ± 2.3, 48.9 ± 1.7, 38.7 ± 1.2 mS at 0, 1, 3, 5, 7 Gy, respectively). Similarly, time-dependent changes in conductance showed a maximal increase occurring in the first 6 hr (46.3 ± 1.5); there was no significant difference with increasing time after irradiation. Treatment with MAAM resulted in a significant decrease in conductance. DP studies showed that MAAM restored ion selectivity. TEM showed disruption of the cell junction complex and formation of clear space between the cells as early as 6 hr after irradiation. The changes persisted for the duration of the experiment (6 days). MAAM prevented cell junction disruption in mice; this was identifiable at 6 hr after irradiation. Western analysis and IHC showed a radiation dose-dependent increase in Claudin 1, 2, 5, Nectin, and E-cadherin except at 7 Gy. MAAM further increased Claudin 1, 2, 5, Nectin, and E-cadherin across all radiation doses. MAAM treatment decreased paracellular permeability. TEM showed disruption of the cell junction complex that peaked at 6 hours and was corrected using MAAM. Western analysis and IHC showed that radiation-induced alterations in the cell junction protein complex were further corrected in the MAAM group. We conclude that the disruption in the barrier results from changes in the cell junction complex and that MAAM restores the barrier function by correcting these changes.